This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City.
This study will combine two drugs (hydroxychloroquine and Bromhexine) to see if hydroxychloroquine is better in combination with Bromhexine in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City. Hydroxychloroquine will be used in a low dose (200 mg every 24 hrs). Bromhexine will be 8mg every 8 hrs. The placebo group will receive only Bromhexine and a sham hydroxychloroquine pill.
Drug: Hydroxychloroquine Sulfate
A daily low dose of Hydroxychloroquine Sulfate
Other Name: Plaquenil
Drug: Bromhexine 8 MG
TMPRSS2 blocker
Other Name: Bisolvon
Inclusion Criteria:
• Health Care workers with high exposure to COVID-19 patients
Exclusion Criteria:
- Allergy to hydroxychloroquine or bromhexine
- History of bone marrow transplant
- Known G6PD deficiency
- Chronic hemodialysis or Glomerular Filtration Rate < 20ml/min
- Psoriasis
- Porphyria
- Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone
- Known history of long QT syndrome
- Current known QTc>500 msec
- Pregnant or nursing
- Severe liver disease
- Seizure disorder